ArticleBritish journal of cancer2004
The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype.
Article in British journal of cancer, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Interleukin-6-174G>C gene promoter polymorphism and prognosis in patients with cancer.Oncotarget · 2017Pooled it
- The IL6-like Cytokine Family: Role and Biomarker Potential in Breast Cancer.Journal of personalized medicine · 2021Review
- STAT3 polymorphisms and IL-6 polymorphism are associated with the risk of basal cell carcinoma in patients from northern Poland.Archives of dermatological research · 2019Article
- Genetic Modifiers of the Breast Tumor Microenvironment.Trends in cancer · 2018Review
- Genetic polymorphisms of IL-6 promoter in cancer susceptibility and prognosis: a meta-analysis.Oncotarget · 2018Article
- Interleukin-6 is a potential therapeutic target in interleukin-6 dependent, estrogen receptor-α-positive breast cancer.Breast cancer (Dove Medical Press) · 2016Article
- IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.BMC cancer · 2014Article
- Genetic modifiers of cancer risk in Lynch syndrome: a review.Familial cancer · 2013Review
- Genetic variation in proinflammatory cytokines IL6, IL6R, TNF-region, and TNFRSF1A and risk of breast cancer.Breast cancer research and treatment · 2011Article
- Interleukin-6 and the IL-6 (-174) C/G polymorphism in breast pathologies and in HIV-infected patients.Archives of medical science : AMS · 2010Article
- PTGS2 and IL6 genetic variation and risk of breast and prostate cancer: results from the Breast and Prostate Cancer Cohort Consortium (BPC3).Carcinogenesis · 2010Article
- The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan.Journal of clinical immunology · 2010Article
- The (-174) G/C polymorphism in the interleukin-6 gene is associated with risk of papillary thyroid carcinoma in Turkish patients.Journal of endocrinological investigation · 2009Article
- The prognostic value of four interleukin-1 gene polymorphisms in Caucasian women with breast cancer: a multicenter study.BMC cancer · 2009Article
- Interleukin-6 expression and gene polymorphism are associated with severity of periodontal disease in a sample of Brazilian individuals.Clinical and experimental immunology · 2007Article
- Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review.BMC cancer · 2006Article
- Interleukin 6 G-174 C polymorphism and breast cancer risk.European journal of epidemiology · 2006Article
- Cystic fibrosis modifier genes.Journal of the Royal Society of Medicine · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum and tissue levels of interleukin-6 (IL-6) have been implicated in the biological phenotype of breast carcinoma. A common G/C polymorphism at position -174 of the IL-6 promoter can influence the expression level of this gene. We therefore investigated for associations between this polymorphism and various phenotypic features in a series of 256 breast cancers. Individuals who were homozygous for the C allele (n=55) were more likely to have higher-grade tumours (P=0.039) with ductal histology (P=0.030) compared to those harbouring at least one wild-type G allele (n=201). Homozygosity for the C allele was also associated with significantly worse overall survival (P=0.031). We conclude that the -174 C allele of IL-6 is associated with a more aggressive breast cancer phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.